Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist

Transplantation

Volumn 80, Issue 1, 2005, Pages 81-87

  Amuchastegui, Susana ^a   Daniel, Kenn C ^a   Adorini, Luciano ^a  

^a BioXell SpA   (Italy)

Author keywords

Allograft vasculopathy; Aortic transplant; Gene microarray; Heart transplant; Vitamin D analogs

Indexed keywords

1 ALPHA FLUORO 25 HYDROXY 16,23E DIENE 26,27 BISHOMO 20 EPI CHOLECALCIFEROL; BXL 628; CALCITRIOL; CD11B ANTIGEN; DEXAMETHASONE; GLYCOPROTEIN P 15095; IMMUNOMODULATING AGENT; MIGLYOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR AGONIST;

ACUTE GRAFT REJECTION; ADVENTITIA; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DENDRITIC CELL; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; GENETIC TRANSCRIPTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MONOTHERAPY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ANIMALS; AORTA; CALCITRIOL; CELL DIVISION; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CALCITRIOL; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 22144431544     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164619.49828.7A     Document Type: Article

References (48)

1. Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J 2001; 15(14): 2579.
2. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8(4): 174.
3. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003; 23: 117.
4. Carlberg C, Polly P. Gene regulation by vitamin D3. Crit Rev Eukaryot Gene Expr 1998; 8(1): 19.
5. Adorini L, Penna G, Giarratana N, et al. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003; 88(2): 227.
6. Penna G, Adorini L. 1,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405.
7. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164(9): 4443.
8. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270(3): 701.
9. Dong X, Craig TA, Xing N, et al. Direct transcriptional regulation of ReIB by 1alpha,25-dihydroxyvitamin D3 and its analogs: Physiologic and therapeutic implications for dendritic cell function. J Biol Chem 2003; 278: 49378.
10. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195(5): 603.
11. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945.
12. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 22: 22.
13. Adorini L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs 2002; 3(10): 1458.
14. Becker BN, Hullett DA, O'Herrin JK, et al. Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation 2002; 74(8): 1204.
15. Lemire JM, Archer DC, Khulkarni A, et al. Prolongation of the survival of murine cardiac allografts by the vitamin D3 analogue 1,25-dihydroxy-delta 16-cholecalciferol. Transplantation 1992; 54(4): 762.
16. Johnsson C, Tufveson G. MC 1288: A vitamin D analogue with immunosuppressive effects on heart and small bowel grafts. Transpl Int 1994; 7: 392.
17. Hullett DA, Cantorna MT, Redaelli C, et al. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 1998; 66(7): 824.
18. Kallio E, Hayry P, Pakkala S. MC1288, a vitamin D analogue, reduces short- and long-term renal allograft rejection in the rat. Transplant Proc 1996; 28(6): 3113.
19. Redaelli CA, Wagner M, Gunter-Duwe D, et al. 1Alpha,25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int 2002; 61(1): 288.
20. Redaelli CA, Wagner M, Tien YH, et al. 1Alpha,25-dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 2001; 34(5): 926.
21. Casteels K, Waer M, Laureys J, et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998; 65(9): 1225.
22. van Etten E, Gysemans C, Verstuyf A, et al. Immunomodulatory properties of a 1,25(OH)(2) vitamin D(3) analog combined with IFNbeta in an animal model of syngeneic islet transplantation. Transplant Proc 2001; 33(3): 2319.
23. Gysemans C, Waer M, Laureys J, et al. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 2001; 33(3): 2365.
24. Veyron P, Pamphile R, Binderup L, et al. Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl Immunol 1993; 1(1): 72.
25. Raisanen-Sokolowski AK, Pakkala IS, Samila SP, et al. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 1997; 63(7): 936.
26. Pinette KV, Yee YK, Amegadzie BY, et al. Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 2003; 3(3): 193.
27. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16(4): 343.
28. Sun H, Valdivia LA, Subbotin V, et al. Improved surgical technique for the establishment of a murine model of aortic transplantation. Microsurgery 1998; 18(6): 368.
29. Merke J, Hofmann W, Goldschmidt D, et al. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 1987; 41(2): 112.
30. Albinsson S, Nordstrom I, Hellstrand P. Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization. J Biol Chem 2004; 279(33): 34849.
31. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14(4): 387.
32. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367.
33. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3(3): 199.
34. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4(1): 24.
35. Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004; 16(2): 127.
36. Alroy I, Towers T, Freedman L. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995; 15: 5789.
37. Cippitelli M, Santoni A. Vitamin D3: A transcriptional modulator of the IFN-gamma gene. Eur J Immunol 1998; 28: 3017.
38. Aschenbrenner JK, Sollinger HW, Becker BN, et al. 1,25-OH(2)D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100(2): 171.
39. Demay M. Muscle: A nontraditional 1,25-dihydroxyvitamin D target tissue exhibiting classic hormone-dependent vitamin D receptor actions. Endocrinology 2003; 144(12): 5135.
40. Endo I, Inoue D, Mitsui T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144(12): 5138.
41. Cresdoli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005; 90(2): 962.
42. Lazaro JB, Bailey PJ, Lassar AB. Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. Genes Dev 2002; 16(14): 1792.
43. Buitrago C, Boland R, de Boland AR. The tyrosine kinase c-Src is required for 1,25(OH)2-vitamin D3 signalling to the nucleus in muscle cells. Biochim Biophys Acta 2001; 1541(3): 179.
44. van Etten E, Branisteanu DD, Verstuyf A, et al. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 2000; 69(9): 1932.
45. O'Herrin JK, Hullett DA, Heisey DM, et al. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002; 22(5-6): 515.
46. Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: A prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002; 73(4): 547.
47. Cantorna MT, Hullett DA, Redaelli C, et al. 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 1998; 66(7): 828.
48. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25- Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173(5): 2909.